Xenon Pharmaceuticals Inc’s recent filing unveils that its PRESIDENT & CEO MORTIMER IAN unloaded Company’s shares for reported $0.9 million on Jan 24 ’25. In the deal valued at $40.20 per share,22,468 shares were sold. As a result of this transaction, MORTIMER IAN now holds 31,302 shares worth roughly $0.92 million.
Then, MORTIMER IAN sold 16,315 shares, generating $660,806 in total proceeds. Upon selling the shares at $40.50, the PRESIDENT & CEO now owns 31,302 shares.
Before that, MORTIMER IAN sold 16,217 shares. Xenon Pharmaceuticals Inc shares valued at $649,977 were divested by the PRESIDENT & CEO at a price of $40.08 per share. As a result of the transaction, MORTIMER IAN now holds 31,302 shares, worth roughly $0.92 million.
Chardan Capital Markets initiated its Xenon Pharmaceuticals Inc [XENE] rating to a Buy in a research note published on May 07, 2025; the price target was $55. A number of analysts have revised their coverage, including Deutsche Bank’s analysts, who began to cover the stock in mid February with a ‘”a Buy”‘ rating. H.C. Wainwright started covering the stock on October 01, 2024. It rated XENE as “a Buy”.
Price Performance Review of XENE
On Tuesday, Xenon Pharmaceuticals Inc [NASDAQ:XENE] saw its stock fall -0.97% to $29.46. Over the last five days, the stock has lost -4.81%. Xenon Pharmaceuticals Inc shares have fallen nearly -24.85% since the year began. Nevertheless, the stocks have fallen -24.07% over the past one year. While a 52-week high of $46.00 was reached on 01/02/25, a 52-week low of $26.74 was recorded on 04/09/25. SMA at 50 days reached $33.73, while 200 days put it at $38.45.
Levels Of Support And Resistance For XENE Stock
The 24-hour chart illustrates a support level at 29.11, which if violated will result in even more drops to 28.75. On the upside, there is a resistance level at 30.14. A further resistance level may holdings at 30.81. The Relative Strength Index (RSI) on the 14-day chart is 34.49, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.78, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 88.65%. Stochastics %K at 12.71% indicates the stock is a buying.
The most recent change occurred on January 04, 2024 when Citigroup began covering the stock and recommended ‘”a Buy”‘ rating along with a $62 price target.
